- Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares traded as high as 142.3 percent, in a range of $25.01 to $29.73 on day volume of 49.46 million shares versus three months average volume of 406.52 thousand shares, closed regular trading session at $29.05. The company shares traded at $28.2, down 2.93 percent in the after-hours trading session.
- Akouos (NASDAQ:AKUS) has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human, pediatric clinical trial of AK-OTOF for the treatment of patients with otoferlin gene (OTOF)-mediated hearing loss. Akouos shares traded as high as 37.14 percent, in a range of $3.15 to $4.80 on day volume of 333.75 thousand shares, closed regular trading session at $4.48. The company shares traded at $4.58, up 2.23 percent in the after-hours trading session.
